INR Therapeutic Range for Mechanical Aortic Valve Replacement
For patients with mechanical aortic valve replacement without additional thromboembolic risk factors, target an INR of 2.5 (range 2.0-3.0). 1
Standard-Risk Patients (No Additional Risk Factors)
- Target INR: 2.5 (range 2.0-3.0) for current-generation mechanical aortic valves 1
- This moderate-intensity anticoagulation provides the optimal balance between preventing thromboembolism and minimizing bleeding risk 1
- Randomized trials demonstrate no difference in embolic events but significantly reduced bleeding compared to higher-intensity anticoagulation (INR 3.0-4.5) 1
Special Case: On-X Mechanical Aortic Valve
- For On-X valves specifically, a lower INR target of 1.5-2.0 plus aspirin 75-100 mg daily may be reasonable starting 3 months after surgery in patients without thromboembolic risk factors 1
- Recent evidence from 2024-2025 supports this lower target, showing 57% reduction in composite adverse events and 85% reduction in major bleeding compared to standard anticoagulation 2
- However, the supporting RCT had an unusually high bleeding rate in the control group, and this remains a Class IIb recommendation 1
High-Risk Patients (With Additional Thromboembolic Risk Factors)
Target INR: 3.0 (range 2.5-3.5) for patients with any of the following risk factors: 1
- Atrial fibrillation
- Previous thromboembolism
- Hypercoagulable state
- Older-generation prosthesis (e.g., ball-in-cage valve)
- Severe left ventricular dysfunction 1
Important Caveat on Higher-Intensity Anticoagulation
Recent 2021 data challenges the higher INR goal for high-risk patients. A Michigan registry study found that higher-intensity anticoagulation (INR goal 3.0) was associated with significantly increased bleeding (adjusted HR 2.52) and worse composite outcomes (adjusted HR 2.58) compared to standard-intensity (INR goal 2.5), with very few thromboembolic events in either group 3. This suggests that standard-intensity anticoagulation (INR 2.5, range 2.0-3.0) may be safer even in patients with additional risk factors, though this contradicts current guideline recommendations and requires further validation.
Key Management Principles
- Specify a single INR target rather than just a range, as this reduces the likelihood of patients consistently hovering at the upper or lower boundaries 1
- The acceptable range is ±0.5 INR units around the target 1
- INR fluctuations are associated with increased complications in patients with prosthetic heart valves 1
- Consider adding aspirin 75-100 mg daily if there is a separate indication for antiplatelet therapy, though this increases bleeding risk 1
Common Pitfall
Do not use direct oral anticoagulants (DOACs) in patients with mechanical valves—vitamin K antagonists (warfarin) are required for lifelong anticoagulation 1